As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely followed lung disease medicine.

The company said additional testing of its nasal sprays found yeast, mold and bacterial contamination, prompting a voluntary ...

Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending ...

Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. "Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment," at 4:21 p.m. ET, ...

Cardamyst is now FDA approved as a self-administered intranasal treatment for acute episodes of paroxysmal supraventricular tachycardia.

Trump and Kennedy told Americans that taking Tylenol while pregnant may cause autism, even though decades of research doesn’t support that. There’s no known single cause for autism spectrum disorder.

Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market ...

Milestone Pharmaceuticals (MIST) announced that the U.S. Food and Drug Administration, FDA, approved its first commercial product, CARDAMYST nasal ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...